FOLH1 and prostate cancer: For example, 177Lu, which is used in the treatment of somatostatin receptor positive tumors (177Lu-DOTATATE) and in the prostate cancer-targeting agent, 177Lu-PSMA, decays by emission of both β-electrons and AE (Hindié et al., 2016).